BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O'Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2022. [PMID: 36001306 DOI: 10.1001/jamapsychiatry.2022.2096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Timmermann C, Bauer PR, Gosseries O, Vanhaudenhuyse A, Vollenweider F, Laureys S, Singer T, Antonova E, Lutz A; Mind and Life Europe (MLE) ENCECON Research Group. A neurophenomenological approach to non-ordinary states of consciousness: hypnosis, meditation, and psychedelics. Trends Cogn Sci 2023;27:139-59. [PMID: 36566091 DOI: 10.1016/j.tics.2022.11.006] [Reference Citation Analysis]
2 Sellers EM, Romach MK. Psychedelics: Science Sabotaged by social media. Neuropharmacology 2023;:109426. [PMID: 36693562 DOI: 10.1016/j.neuropharm.2023.109426] [Reference Citation Analysis]
3 Stokłosa I, Więckiewicz G, Stokłosa M, Piegza M, Pudlo R, Gorczyca P. Medications for the Treatment of Alcohol Dependence—Current State of Knowledge and Future Perspectives from a Public Health Perspective. IJERPH 2023;20:1870. [DOI: 10.3390/ijerph20031870] [Reference Citation Analysis]
4 Gukasyan N. On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression. Med (N Y) 2023;4:8-9. [PMID: 36640755 DOI: 10.1016/j.medj.2022.12.003] [Reference Citation Analysis]
5 Alper K, Cange J, Sah R, Schreiber-Gregory D, Sershen H, Vinod KY. Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice. Front Pharmacol 2022;13:1074633. [PMID: 36686713 DOI: 10.3389/fphar.2022.1074633] [Reference Citation Analysis]
6 Kelly JR, Clarke G, Harkin A, Corr SC, Galvin S, Pradeep V, Cryan JF, O'Keane V, Dinan TG. Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis. Int J Clin Health Psychol 2023;23:100349. [PMID: 36605409 DOI: 10.1016/j.ijchp.2022.100349] [Reference Citation Analysis]
7 Fadahunsi N, Knudsen GM, Clemmensen C. Do psychedelics have therapeutic potential for obesity? Nat Rev Endocrinol 2023;19:1-2. [PMID: 36329153 DOI: 10.1038/s41574-022-00769-1] [Reference Citation Analysis]
8 Holoyda BJ. Malpractice and Other Civil Liability in Psychedelic Psychiatry. Psychiatr Serv 2023;74:92-5. [PMID: 36587277 DOI: 10.1176/appi.ps.20220528] [Reference Citation Analysis]
9 Serreau R, Amirouche A, Benyamina A, Berteina-Raboin S. A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe. Pharmaceuticals (Basel) 2022;16. [PMID: 36678537 DOI: 10.3390/ph16010040] [Reference Citation Analysis]
10 Carhart-Harris RL, Chandaria S, Erritzoe DE, Gazzaley A, Girn M, Kettner H, Mediano PAM, Nutt DJ, Rosas FE, Roseman L, Timmermann C, Weiss B, Zeifman RJ, Friston KJ. Canalization and plasticity in psychopathology. Neuropharmacology 2022;226:109398. [PMID: 36584883 DOI: 10.1016/j.neuropharm.2022.109398] [Reference Citation Analysis]
11 Willms J, McCauley B, Kerr L, Presto P, Arun A, Shah N, Irby K, Strawn M, Kopel J. Case report: Medical student types journals during ketamine infusions for suicidal ideation, treatment-resistant depression, post-traumatic stress disorder, and generalized anxiety disorder. Front Psychiatry 2022;13:1020214. [PMID: 36620675 DOI: 10.3389/fpsyt.2022.1020214] [Reference Citation Analysis]
12 Marks M. The varieties of psychedelic law. Neuropharmacology 2022;226:109399. [PMID: 36565855 DOI: 10.1016/j.neuropharm.2022.109399] [Reference Citation Analysis]
13 Kelly DF, Heinzerling K, Sharma A, Gowrinathan S, Sergi K, Mallari RJ. Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology. Neurosurgery 2022;Publish Ahead of Print. [DOI: 10.1227/neu.0000000000002275] [Reference Citation Analysis]
14 Bove GM, Mokler DJ. Effects of a single dose of psilocybin on cytokines, chemokines and leptin in rat serum. JPS 2022. [DOI: 10.1556/2054.2022.00230] [Reference Citation Analysis]
15 Moujaes F, Preller KH, Ji JL, Murray JD, Berkovitch L, Vollenweider FX, Anticevic A. Towards mapping neuro-behavioral heterogeneity of psychedelic neurobiology in humans. Biol Psychiatry 2022:S0006-3223(22)01805-4. [PMID: 36715317 DOI: 10.1016/j.biopsych.2022.10.021] [Reference Citation Analysis]
16 Marseille E, Bertozzi S, Kahn JG. The economics of psychedelic-assisted therapies: A research agenda. Front Psychiatry 2022;13:1025726. [PMID: 36545038 DOI: 10.3389/fpsyt.2022.1025726] [Reference Citation Analysis]
17 Passie T, Guss J, Krähenmann R. Lower-dose psycholytic therapy – A neglected approach. Front Psychiatry 2022;13. [DOI: 10.3389/fpsyt.2022.1020505] [Reference Citation Analysis]
18 Gukasyan N, Schreyer CC, Griffiths RR, Guarda AS. Psychedelic-Assisted Therapy for People with Eating Disorders. Curr Psychiatry Rep 2022;24:767-75. [PMID: 36374357 DOI: 10.1007/s11920-022-01394-5] [Reference Citation Analysis]
19 Maccallum CA, Lo LA, Pistawka CA, Deol JK. Therapeutic use of psilocybin: Practical considerations for dosing and administration. Front Psychiatry 2022;13. [DOI: 10.3389/fpsyt.2022.1040217] [Reference Citation Analysis]
20 O'Donnell KC, Mennenga SE, Owens LT, Podrebarac SK, Baron T, Rotrosen J, Ross S, Forcehimes AA, Bogenschutz MP. Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial. Contemp Clin Trials 2022;123:106976. [PMID: 36332827 DOI: 10.1016/j.cct.2022.106976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Olsen AS, Lykkebo-Valløe A, Ozenne B, Madsen MK, Stenbæk DS, Armand S, Mørup M, Ganz M, Knudsen GM, Fisher PM. Psilocybin modulation of time-varying functional connectivity is associated with plasma psilocin and subjective effects. Neuroimage 2022;264:119716. [PMID: 36341951 DOI: 10.1016/j.neuroimage.2022.119716] [Reference Citation Analysis]
22 Ortiz Bernal AM, Raison CL, Lancelotta RL, Davis AK. Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence. Front Psychiatry 2022;13. [DOI: 10.3389/fpsyt.2022.1049643] [Reference Citation Analysis]
23 Messell C, Summer L, Bonde LO, Beck BD, Stenbæk DS. Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives. Front Psychol 2022;13. [DOI: 10.3389/fpsyg.2022.873455] [Reference Citation Analysis]
24 Bedford P, Hauke DJ, Wang Z, Roth V, Nagy-huber M, Holze F, Ley L, Vizeli P, Liechti ME, Borgwardt S, Müller F, Diaconescu AO. The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity.. [DOI: 10.1101/2022.11.01.514687] [Reference Citation Analysis]
25 Danias G, Appel J. A Google Trends analysis of public interest in psilocybin in the context of the COVID-19 pandemic (Preprint).. [DOI: 10.2196/preprints.43850] [Reference Citation Analysis]
26 Jensen ME, Stenbæk DS, Juul TS, Fisher PM, Ekstrøm CT, Knudsen GM, Fink-Jensen A. Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial). BMJ Open 2022;12:e066019. [PMID: 36241352 DOI: 10.1136/bmjopen-2022-066019] [Reference Citation Analysis]
27 . Error in Race and Ethnicity Data. JAMA Psychiatry. [DOI: 10.1001/jamapsychiatry.2022.2982] [Reference Citation Analysis]
28 Mellner C, Dahlen M, Simonsson O. Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample. Int J Environ Res Public Health 2022;19. [PMID: 36141631 DOI: 10.3390/ijerph191811353] [Reference Citation Analysis]